title: Benefit/risk assessment of biologic monotherapy vs combination therapy in Crohn's Remains Challenging.
authors: IBD Center, Boston, Massachusetts.
authors: Athos
authors: A
authors: Bousvaros
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D009369:Neoplasms / Q000139:chemically induced*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007155:Immunologic Factors